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cardiovascular risk factor appeared to influence the expansion pattern.
Eccentric thrombus was associated with a greater incidence of continuous
growth (P  0.05).
Comment: This study confirms what most of us have observed. AAAs
expand unpredictably, making continuous and regular follow up required.
In my experience small AAAs are the ones most likely to exhibit an irregular
growth pattern, with larger aneurysms seeming to expand more steadily and
more rapidly. It was a bit of a surprise that the percentage of small AAAs
exhibiting an irregular growth pattern was so high, 88%. With that excep-
tion, however, the data really did not tell us anything terribly surprising or
new. The data do, however, provide justification for regular follow up of
small AAAs no matter what their previous growth pattern.
Polymorphisms Associated With Cholesterol and Risk of Cardiovascular
Events
Kathiresan S, Melander O, Anevski D, et al. N Engl J Med 2008;358:
1240-9.
Conclusion: A genotype score of validated single-nucleotide polymor-
phisms (SNPs) of LDL or HDL cholesterol is an independent risk factor for
cardiovascular (CV) disease.
Summary: There are single-nucleotide polymorphisms (SNPs) associ-
ated with blood levels of low density lipoprotein (LDL) and high density
lipoprotein (HDL) cholesterol. These polymorphisms modestly affect lipid
levels. The authors studied whether a combination of SNPs can contribute
to risk of CV disease. Single-nucleotide polymorphisms at nine loci in 5414
subjects were studied. The patients were derived from a CV cohort of the
Malmö Diet and Cancer Study. Initially associations between SNPs and
HDL and LDL cholesterol were validated. A genotype score based on the
number of unfavorable alleles was developed. A Cox proportional-hazards
model was then used to determine the time to the first CVevent in relation-
ship to the genotype score.
Levels of either LDL or HDL cholesterol all were associated with all
nine of the SNPs. The level of LDL cholesterol increased from 152 to 171
mg/dl with increasing genotype score. HDL cholesterol decreased from 60
mg/dl to 51 mg/dl with increasing genotype score. At a median follow up
of 10.6 years 238 subjects had a first CV event. Genotype score was
associated with the first CVevent in the model when adjusted for covariances
including baseline lipid levels (P 0.001). Genotype score did not improve
clinical risk projection. There was improvement in risk classification with the
use of models that included the genotype score.
Comment: Single measurements of blood lipid levels may not accurately
reflect effects of lifetime exposure to elevated cholesterol. Genotypes, however,
are invariant over time and can be preciselymeasured on a single assay. Itmay be
therefore, that a panel of polymorphisms associated with levels of HDL or LDL
cholesterol may eventually provide more precise prediction of cardiovascular
outcomes than LDL orHDL levels alone. In this study the authors assign equal
weight to genotype score for each unfavorable allele regardless of the effect of
each on cholesterol levels. Therefore, the effects of various allelesmay have been
over- or under-estimated. Future research will clarify the true effect on choles-
terol levels of each unfavorable allele.
Drug-Eluting Stents vs Coronary-Artery Bypass Grafting in Multivessel
Coronary Disease
Hannan EL, Wu C, Walford G, et al. N Engl J Med 2008;358:331-41.
Conclusion: Treatment of patients with multi vessel coronary disease
with coronary artery bypass (CABG) results in lower mortality rates than
does treatment with drug-eluting stents. CABG is also associated with lower
rates of myocardial infarction, death and repeat revascularization.
Summary: The authors sought to compare the efficacy of CABG and
coronary stenting in the era of drug-eluting stents. Patients with multi vessel
coronary disease in New York state betweenOctober 1, 2003 andDecember
31, 2004, and who were treated with drug-eluting stents or CABG were
identified. Adverse outcomes defined as death, death or myocardial infarc-
tion, or repeat revascularization occurring through December 31, 2005,
were compared in the two groups. Adjustments were made for differences in
risk.
CABG, in comparison to drug-eluting stents, was associated with lower
18 month rates of death, and rates of death or myocardial infarction in
patients with two and three vessel coronary disease. In patients with three
vessel disease who underwent CABG the adjusted hazard ratio for death
compared to those who received stents was 0.8 (95% CI 0.65-0.97).
Adjusted survival rate was 94% versus 92.7% (P 0.03). The adjusted hazard
ratio for myocardial infarction or death was 0.75 (95% CI 0.63-0.89). The
adjusted survival free from myocardial infarction was 92.1% in those treated
with CABG versus 89.7% in those treated with stents (P  0.001). In the
patients with two vessel coronary disease who underwent CABG opposed to
those who received a stent adjusted hazard ratio for death was 0.71 (95% CI
0.57-0.89). Adjusted survival rate was 96% versus 94.6% (P  0.003). The
adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI
0.59-0.87). Adjusted survival rate free frommyocardial infarction was 94.5%
versus 92.5% (P 0.001). Rates of revascularization were also lower in those
patients undergoing CABG versus those having stent placement.
Comment: This observational study compared off label use of drug-
eluting stents to CABG. The data affirm the fact that CABG is the standard
for care for those who require multi vessel coronary revascularization. For
properly informed patients who wish a less invasive alternative stents may
also be considered.
Local Delivery of Paclitaxel to Inhibit Re-Stenosis During Angioplasty
of the Leg
Tepe G, Zeller T, Albrecht T, et al. N Eng J Med 2008;358:689-99.
Conclusion: Performance of percutaneous angioplasty of the superfi-
cial femoral artery (SFA) using Paclitaxel-coated angioplasty balloons results
in significant reductions in late lumen loss and target lesion revasculariza-
tion.
Summary: A previous trial of a sirolimus-coated stents for SFA angio-
plasty failed to reveal benefit when compared to un-coated stents (Circ
2002;106:1505-9). There have, however, been animal trials that the use of
Paclitaxel as a coating on angioplasty balloons and also when added to
contrast media, can reduce vascular smooth muscle cell proliferation and
therefore decrease intimal hyperplasia. In this study the authors investigated
the use of Paclitaxel-coated angioplasty balloons and the addition of Pacli-
taxel to contrast media on lower extremitiy angioplasty.
This trial randomly assigned 154 patients with stenosis or occlusion of
the femoral/popliteal artery to treatment with standard balloon catheters
coated with Paclitaxel, treatment with uncoated balloons but with Paclitaxel
dissolved in the contrast medium, or to treatment with uncoated balloons
without Paclitaxel in the contrast medium (control group). Three centers in
Germany participated in the study. The study was sponsored by Bavaria
Medizintecnologie and Schering, Germany. The primary end point was
lumen loss at six months.
Mean age of the patients was 68  8 years. Forty nine percent of the
patients had diabetes. Of the lesions treated, 27% were total occlusions and
36%were restenotic lesions.Mean lesion length was 7.4 6.5 cm. The study
groups had no significant demographic differences. All patients received 75
mg of Clopidogril daily for four weeks after intervention, and 100 mg of
aspirin daily indefinitely. Plasma Paclitaxel concentrations were determined
immediately and two hours after intervention, using high performance
liquid choromatography. Residual Paclitaxel on the balloon after use was
also determined. Fifty four patients were assigned to the control group, 48
to treatment with Paclitaxel-coated balloons, and 52 to treatment with
Paclitaxel in the contrast medium. Mean ankle-brachial index prior to
intervention was 0.5 0.3. Late lumen loss was determined by angiography
and 83% of the patients underwent angiography at six months of follow-up.
At six months, mean late lumen loss in the control group was 1.7 1.8
mm. In the group treated with Paclitaxel-coated balloons it was 0.4  1.2
mm (P  0.001). In the group treated with Paclitaxel only in the contrast
medium mean late lumen loss at six months was 2.2  1.6 mm (P  0.11
compared to the control group). Revascularization of target lesions at six
months was 37% in the control group, 4% in the group treated with
Paclitaxel-coated balloons (P  0.001), and 29% in the group treated with
Paclitaxel only in the contrast medium (P  0.41). At 24 months, revascu-
larization rates increased to 52% in the control group, 15% in the group
treated with Paclitaxel-coated balloons, and 40% in the group treated with
Paclitaxel in the contrast medium. Maximum plasma Paclitaxel concentra-
tion remained below detectable limits in 40 of 42 patients treated with
coated balloons. The majority of patients with Paclitaxel in the contrast
medium had measurable plasma concentrations immediately after the pro-
cedure.
Comment: The results of this study seem almost too good to be
believed. Nevertheless, based on the animal data, they are not inconceivable.
The investigators, however, were not fully blinded to the treatment arm of
the individual patients. Some also served as consultants and received grant
support from the industry sponsors or are involved in patent applications
with respect to the techniques used in the trial. Fully blinded studies with
non-potentially biased investigators will be required.
Genetic Determinants of Response to Warfarin During Initial
Anticoagulation
Schwartz UI, Ritchie MD, Bradford Y, et al. N Engl J Med 2008;358:999-
1008.
Conclusion: Initial variability of the international normalized ratio
(INR) in response to warfarin therapy is most commonly associated with the
pharmacologic target of warfarin rather than with generic variants determin-
ing warfarin metabolism.
Summary: Warfarin is metabolized by cytochrome T-4502C9
(CYP2C9) and genetic variants of CYP2C9. A key pharmacologic target of
warfarin is vitamin K epoxide reductase (BKORC1). Both the metabolism of
warfarin and the response to its pharmacologic targets contribute to the INR
response during initial anticoagulation. The precise role of these genetic
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